Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs
- 8 September 2021
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 36 (12) , 2888-2900
Abstract
Background: Parkinson's disease (PD) is characterized by heterogeneous motor and nonmotor manifestations related to alterations in monoaminergic neurotransmission systems. Nevertheless, the characterization of concomitant dopaminergic and serotonergic dysfunction after different durations of Parkinson's disease, as well as their respective involvement in the expression and severity of neuropsychiatric signs, has gained little attention so far.Methods: To fill this gap, we conducted a cross‐sectional study combining clinical and dual‐tracer positron emission tomography (PET) neuroimaging approaches, using radioligands of dopamine ([11C]‐N‐(3‐iodoprop‐2E‐enyl)‐2‐beta‐carbomethoxy‐3‐beta‐(4‐methylphenyl)‐nortropane) ([11C]PE2I) and serotonin ([11C]‐N,N‐dimethyl‐2‐(‐2‐amino‐4‐cyanophenylthio)‐benzylamine) ([11C]DASB) reuptake, after different durations of Parkinson's disease (ie, in short‐disease duration drug‐naive de novo (n = 27, 0–2 years‐duration), suffering from apathy (n = 14) or not (n = 13); intermediate‐disease duration (n = 15, 4–7 years‐duration) and long‐disease duration, non‐demented (n = 15, 8–10 years‐duration) patients). Fifteen age‐matched healthy subjects were also enrolled.Results: The main findings are threefold: (1) both dopaminergic and serotonergic lesions worsen with the duration of Parkinson's disease, spreading from midbrain/subcortical to cortical regions; (2) the presence of apathy at PD onset is associated with more severe cortical and subcortical serotonergic and dopaminergic disruption, similar to the denervation pattern observed in intermediate‐disease duration patients; and (3) the severity of parkinsonian apathy, depression, and trait‐anxiety appears primarily related to serotonergic alteration within corticostriatal limbic areas.Conclusions: Altogether, these findings highlight the prominent role of serotonergic degeneration in the expression of several neuropsychiatric symptoms occurring after different durations of Parkinson's disease. © 2021 International Parkinson and Movement Disorder SocietyKeywords
Funding Information
- Fondation pour la Recherche Médicale (DEQ20110421326)
- French National Research Agency
This publication has 57 references indexed in Scilit:
- Progression of monoaminergic dysfunction in Parkinson's disease: A longitudinal 18F-dopa PET studyNeuroImage, 2011
- Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to DisabilityThe Scientific World Journal, 2011
- Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET studyNeurobiology of Disease, 2010
- Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET studyBrain, 2009
- Construction and validation of a dimensional scale exploring mood disorders: MAThyS (Multidimensional Assessment of Thymic States)BMC Psychiatry, 2008
- Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C]DASBMovement Disorders, 2008
- Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography studyAnnals of Neurology, 2007
- The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Regional distribution of serotonin transporter protein in postmortem human brainNuclear Medicine and Biology, 2005
- Age and severity of nigrostriatal damage at onset of Parkinson's diseaseSynapse, 2002